Key result
New LC-MS/MS method successfully quantifies Lusutrombopag in rat plasma for preclinical pharmacokinetic studies.
A novel, sensitive LC-MS/MS method was successfully developed and validated for the pharmacokinetic evaluation of Lusutrombopag in rats.
Facilitates rat PK studies of Lusutrombopag; leaves open human validation and clinical adoption.
A novel, simple and sensitive method for the determination of Lusutrombopag in rat plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was developed and validated. The determination was performed on an API4000 triple quadrupole mass spectrometry in the multiple reaction monitoring mode using the respective [M+H] + ions m / z 593.1 → 272.3 for Lusutrombopag. The limit of detection was 0.5 ng/mL, and the lower limit of quantification was 2.0 ng/mL in rat plasma. Good linearity was obtained over the range of 2.0–150.0 ng/mL and the correlation coefficient was found to be 0.9998. The intra and inter-day precisions were found to be 3.8–6.9% and 6.8–10.5%, respectively. The intra and inter-day accuracy derived from QC samples was found to be 2.5–4.9% and 5.5–7.2%, respectively. The analyte was stable under various conditions (at room temperature, during freeze-thaw, in the autosampler and under deep-freeze conditions). The F -test and t -test at 95% confidence level were subjected on data for statistical analysis. The developed method was successfully applied to the pharmacokinetic study in rats.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2019) studied this question. Lusutrombopag was evaluated on Method validation for determination of Lusutrombopag in rat plasma. A novel LC-MS/MS method for determining Lusutrombopag in rat plasma was developed and validated, demonstrating good linearity (2.0-150.0 ng/mL) and successful application to pharmacokinetic studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: